InsidersTradesSigma
Follow the KYNTRA BIO, INC. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was disclosed on 9 September 2026 (Retenue fiscale). Among the most active insiders: DeLucia David. Every trade is accessible without an account.
Analysts rate KYNTRA BIO, INC. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
KYNTRA BIO, INC. 是一家生物技术公司，专注于开发慢性疾病的创新疗法。该公司在纳斯达克上市，股票代码为 KYNTRA。